A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with
advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
Phase:
Phase 1
Details
Lead Sponsor:
MBQ Pharma
Collaborator:
Congressionally Directed Medical Research Programs